Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
Details : Pasireotide Diaspartate is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Post-Bariatric, Hypoglycemia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 03, 2023
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy Study of SOM230 s.c. in Cluster Headache
Details : Pasireotide Diaspartate is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cluster Headache.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 02, 2015
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pasireotide Diaspartate is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 20, 2012
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pasireotide Diaspartate is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dumping Syndrome.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 11, 2012
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pasireotide Diaspartate is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Kidney Diseases.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 17, 2012
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma
Details : Pasireotide Diaspartate is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
April 05, 2011
Lead Product(s) : Pasireotide Diaspartate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
